Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder ...

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...

A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder ...

Immunotherapy is a modern approach to cancer treatment that uses a patient's own immune system to help fight tumors. It has ...

What are the symptoms of bladder cancer – and how is it treated? - The most common symptom of bladder cancer is blood in your ...

Immunotherapy is a modern approach to cancer treatment that uses a patient's own immune system to help fight tumors.

Matthew R. Zibelman, MD, discusses treatment options in muscle-invasive, perioperative, and metastatic bladder cancer.

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

Outcome of BCG immunotherapy of bladder cancer may ultimately depend on imbalance of Th1/Th17–Th2–regulatory T-cell axis. It is important to determine the expression and potential role of ...